Bio­gen spin­off be­gins trad­ing to­day; New on­col­o­gy chief at As­traZeneca

• Shares of Bio­gen’s he­mo­phil­ia spin­off Biover­a­tiv be­gan trad­ing to­day on a “when is­sued” ba­sis and will be­gin reg­u­lar trad­ing on Feb­ru­ary 2nd un­der …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA